Compare Invesco DB Oil Fund (DBO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs Sanofi SA — how do they compare? Invesco DB Oil Fund trades at $24.04 (market cap $255.13M), while Sanofi SA trades at $40.21 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 373.1× Invesco DB Oil Fund's market cap, and Sanofi SA pays a 6.01% dividend while Invesco DB Oil Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and Sanofi SA for 94 Days on average.
| DBO | SNY | |
|---|---|---|
Market Cap | $255.13M | $95.18B |
Volume | 562,167 | 2,995,646 |
Sector | Commodities - Energy | Health |
52-Week High | $26.35 | $52.34 |
52-Week Low | $11.98 | $39.51 |
Typical Hold Time | 31 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO trades at $23.54, down 0.42% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance at $24 and support at $23, while moving averages signal bearish momentum. Recent oil market developments, including Middle East tensions and OPEC+ production decisions, create a volatile backdrop for energy stocks.
The outlook remains cautious given geopolitical risks and mixed oil price signals. Investment opportunities exist if supply disruptions persist, but risks include potential price declines from strategic reserve releases and ongoing legal challenges facing the oil industry.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
